Table 3.

Patients in whom CMV-specific CTL were measured at one time point at least 6 months after allografting

Group/patient no.DonorHLA alleleCMV-specific CTLCMV reactivation (days after SCT)GVHD gradeFollow-up
(days after SCT)
As % of CD8+ count at peakPeak absolute cell count (× 105)
Group 1 (recipient +/donor + for CMV)        
 25 V  A2 4.9 47 82 III 550 
 26 S  B7 0.4 7 ND I 1030 
 27 S  A2; B7 0; 0.4 0; 28 ND I 247 
 28 S  B7 12.7 1525 ND II 1029 
 29 S  A2; B7 0.1; 1.1 1.6; 22 ND II 1395  
 30 S  A2; B7 1.3; 8 72; 442 42 III 688 
 31 S  A2 2.5 117 47 & 139 III 338 
 32 S  A2 6 300 31 0 280 
 33 S  A2; B7 ND ND 52 II 516  
Group 2 (recipient +/donor − for CMV)        
 34 V  A2; B7 0.1; 3.1 44; 1463 85 & 122 II 990  
 35 S  A2 1.8 89 87 0 1260 
 36 V  A2 2.7 25 55 II 247 
 37 S  A2 ND ND ND 0 732 
Group 3 (recipient −/donor + for CMV)        
 38 S  A2; B7 1.2; 1.5 82; 102 56 & 120 II 337 
 39 S  A2 ND ND ND 0 392 
Group/patient no.DonorHLA alleleCMV-specific CTLCMV reactivation (days after SCT)GVHD gradeFollow-up
(days after SCT)
As % of CD8+ count at peakPeak absolute cell count (× 105)
Group 1 (recipient +/donor + for CMV)        
 25 V  A2 4.9 47 82 III 550 
 26 S  B7 0.4 7 ND I 1030 
 27 S  A2; B7 0; 0.4 0; 28 ND I 247 
 28 S  B7 12.7 1525 ND II 1029 
 29 S  A2; B7 0.1; 1.1 1.6; 22 ND II 1395  
 30 S  A2; B7 1.3; 8 72; 442 42 III 688 
 31 S  A2 2.5 117 47 & 139 III 338 
 32 S  A2 6 300 31 0 280 
 33 S  A2; B7 ND ND 52 II 516  
Group 2 (recipient +/donor − for CMV)        
 34 V  A2; B7 0.1; 3.1 44; 1463 85 & 122 II 990  
 35 S  A2 1.8 89 87 0 1260 
 36 V  A2 2.7 25 55 II 247 
 37 S  A2 ND ND ND 0 732 
Group 3 (recipient −/donor + for CMV)        
 38 S  A2; B7 1.2; 1.5 82; 102 56 & 120 II 337 
 39 S  A2 ND ND ND 0 392 

For patients who were positive for both HLA A*0201 and HLA B*0702, the results for the HLA A*0201 tetramer are shown first, followed by the results for the B*0702 tetramer.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal